Capital is being raised repeatedly to resource pipeline development, with financing events rather than durable profitability visible in the retrieved sources.
Insufficient public data available on ROIC and cost-per-outcome; retrieved sources provide concrete financing amounts (e.g., $50M Series C closing in 2020 and $25M private placement in 2023) but not detailed capital-efficiency metrics.
Closing of $50M Series C financing (Aug 24, 2020): Provided proceeds to support company development; specific downstream value creation (clinical readouts attributable to the financing) is not quantified in the retrieved sources.
$25M private placement (announced Dec 11, 2023): Raised additional funding at a stated warrant price ($3.1499 per warrant) and was described as enabling further resourcing of a portfolio (SMARCA2 portfolio advancement referenced in snippet).
ATM to raise up to $25M (filed Mar 12, 2026): Provides optionality to raise capital; investor reception and ultimate draw amount are not provided in the retrieved sources.
Prelude’s capital allocation appears oriented toward sustaining pipeline investment rather than generating near-term profits, consistent with a clinical-stage oncology company. Public financing headlines include a $50M Series C closing in 2020 and a $25M private placement in 2023, both attributed to CEO Kris Vaddi in releases/snippets. In 2026, Prelude filed an at-the-market program that could raise up to $25M, indicating continued reliance on equity-linked financing to fund development needs. The retrieved sources do not provide enough detail to evaluate cost control rigor, margin improvement plans, or ROIC outcomes with specificity.
equity fundedcapital raises
